PD-1/PD-L1抑制剂治疗淋巴瘤的研究进展  

Research progress of PD-1/PD-L1 inhibitor in the treatment of lymphoma

作　　者：何艳霞 闫俊 王佳其 王彦茹 张清媛[1] 张悦[1] He Yanxia;Yan Jun;Wang Jiaqi;Wang Yanru;Zhang Qingyuan;Zhang Yue(Department of Oncology,Affiliated Tumor Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China.)

机构地区：[1]哈尔滨医科大学附属肿瘤医院肿瘤内科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2018年第20期3318-3321,共4页Journal of Modern Oncology

基　　金：黑龙江省自然科学基金重点项目(编号:ZD2016018)

摘　　要：免疫检查点抑制剂已被批准用于多种难治性实体肿瘤的治疗,如恶性黑色素瘤、肺癌、胰腺癌、肾癌等。其在复发/难治性淋巴瘤的治疗方面也展现出广阔的应用前景。程序性死亡受体-1及其配体(PD-1/PD-L1)通路是免疫检查点抑制治疗(checkpoint blockade therapy,CBT)的关键性通路之一。肿瘤细胞可通过PD-1/PD-L1通路抑制T细胞活性,阻断免疫应答,从而实现免疫逃逸,最终促进肿瘤的发生、发展。新近研究发现PD-1/PD-L1通路在复发/难治性霍奇金淋巴瘤(Hodgkin lymphoma,HL)和部分非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)中也发挥着重要作用。本文将简单介绍PD-1/PD-L1通路的生物学活性,总结针对该通路的免疫疗法在恶性淋巴瘤治疗中的研究进展。Immune checkpoint inhibitors have been approved for use in the treatment of all kinds of refractory solid tumors such as melanoma, lung cancer, pancreatic cancer, kidney cancer, etc. It also has gained broad prospects in the therapy of relapse/refractory lymphoma. The programmed death - 1 and its ligand （ PD-1/PD-L1 ） have emerged as one of the critical pathways of immune checkpoint inhibition therapy （CBT）. Tumor cells can engage PD1/PD-L1 pathway to inhibit the activity of T cells, block the immune response, thereby achieving immune escape, and ultimately promote the occurrence and development of tumors. Recent studies have found that PD-1/PD-L1 pathway also plays an important role in recurrent/refractory Hodgkin lymphoma （HL） and some of non-Hodgkin lymphoma （NHL）. This article will briefly introduce the biological activity of the PD-1/PD-L1 pathway and summarize the progress of the immunotherapy in the treatment of malignant lymphoma.

关 键 词：淋巴瘤 免疫检查点 程序性死亡受体-1 程序性死亡受体配体-1 

分 类 号：R733.4[医药卫生—肿瘤]